CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137
in treating patients with solid tumors, including central nervous system (CNS) tumors or
lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs,
such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking
these signals can affect many functions of the cell, including cell division and cell death,
and may kill cancer cells.